Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Sarcoma 1Neuroblastoma 1Lymphoma 1Leukemia 1Central Nervous System Neoplasms 1

Interventions

Cyclophosphamide 16Filgrastim 15Etoposide 10Carboplatin 10Peripheral Blood Stem Cell Transplantation 8Melphalan 8Magnetic Resonance Spectroscopy 7Granulocyte Colony-Stimulating Factor 7Busulfan 7Thiotepa 6Temozolomide 6Radiotherapy 6Ifosfamide 6etoposide phosphate 5X-Rays 5Topotecan 5Phantoms, Imaging 5Doxorubicin 5Cisplatin 5Vincristine 4Specimen Handling 4Nuclear Medicine Department, Hospital 4Mesna 4selpercatinib 3sargramostim 3pembrolizumab 3palbociclib 3aldesleukin 3Sirolimus 3Radiosurgery 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × Fenofibrate × CNS × Clear all
NCT00357500 2014-10-01

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
101 enrolled 10 charts
CNSLymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Neuroblastoma, Sarcoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡